SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rebbeck TR,Friebel T,Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004; 22: 10551062.
  • 2
    Meijers-Heijboer H,van Geel B,van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345: 159164.
  • 3
    Goldflam K,Hunt KK,Gershenwald JE, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004; 101: 19771986.
  • 4
    McDonnell SK,Schaid DJ,Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001; 19: 39383943.
  • 5
    Hartmann LC,Schaid DJ,Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999; 340: 7784.
  • 6
    Hartmann LC,Sellers TA,Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001; 93: 16331637.
  • 7
    Stolier AJ,Corsetti RL. Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation. Am Surg. 2005; 71: 10311033.
  • 8
    Tuttle TM,Habermann E,Grund E,Morris T,Virnig B. Increasing use of contralateral prophylactic mastectomy among breast cancer patients: a trend toward more aggressive surgical treatment. Ann Surg Oncol. 2007; 14: 7.
  • 9
    Giuliano AE,Jones RC,Brennan M,Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997; 15: 23452350.
  • 10
    Lyman GH,Giuliano AE,Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005; 23: 77037720.
  • 11
    Dupont EL,Kuhn MA,McCann C,Salud C,Spanton JL,Cox CE. The role of sentinel lymph node biopsy in women undergoing prophylactic mastectomy. Am J Surg. 2000; 180: 274277.
  • 12
    Cody HS3rd. Clinical aspects of sentinel node biopsy. Breast Cancer Res. 2001; 3: 104108.
  • 13
    Alvardo MD,Cox CE,Carter WB,Hoover S,Laronga CH. Use of sentinel lymph node biopsy in a prophylactic mastectomy setting. Breast Cancer Res Treat. 2006; 100( suppl 1): S82.
  • 14
    Boughey JC,Khakpour N,Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006; 107: 14401447.
  • 15
    Soran A,Falk J,Bonaventura M,Keenan D,Ahrendt G,Johnson R. Is routine sentinel lymph node biopsy indicated in women undergoing contralateral prophylactic mastectomy? Magee-Womens Hospital experience. Ann Surg Oncol. 2007; 14; 646651.
  • 16
    Schrenk P,Wolfl S,Bogner S,Huemer GM,Wayand W. Symmetrization reduction mammaplasty combined with sentinel node biopsy in patients operated for contralateral breast cancer. J Surg Oncol. 2006; 94: 915.
  • 17
    Lucci A,Mackie L,Beitsch P, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection, versus SLND alone in The American College of Surgeons Oncology Group (ACOSOG) Trial Z0011. J Clin Oncol. 2007; 25: 36573663.
  • 18
    Wilke LG,McCall LM,Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective International Cooperative Group trial. Ann Surg Oncol. 2006; 13: 491500.
  • 19
    Fleissig A,Fallowfield LJ,Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006; 95: 279293.
  • 20
    Veronesi U,Paganelli G,Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349: 546553.
  • 21
    Schrenk P,Rieger R,Shamiyeh A,Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000; 88: 608614.
  • 22
    Gershenwald JE,Hunt KK,Kroll SS, et al. Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Ann Surg Oncol. 1998; 5: 529538.
  • 23
    King TA,Ganaraj A,Fey JV, et al. Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy. Cancer. 2004; 101: 926933.
  • 24
    Black DS,Specht M.Lee JM, et al. Detecting occult breast cancer in prophylactic mastectomies: sentinel node biopsy vs preoperative MRI. Ann Surg Oncol. 2007; 14: 24772484.
  • 25
    Petitti DB. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis. 2nd ed. New York, NY: Oxford University Press; 2000.
  • 26
    Hunink MGG,Siegel P,Weeks JE, et al. Decision Making in Health and Medicine: Integrating Evidence and Values. New York, NY: Cambridge University Press; 2001.
  • 27
    O'Hea BJ,Hill AD,El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg. 1998; 186: 423427.
  • 28
    Hill AD,Tran KN,Akhurst T, et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg. 1999; 229: 528535.
  • 29
    Chagpar AB,Martin RC,Scoggins CR, et al. Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery. 2005; 138: 5663.
  • 30
    Posther KE,McCall LM,Blumencranz PW, et al. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005; 242: 593599; discussion 599–602.
  • 31
    Cox CE,Pendas S,Cox JM, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg. 1998; 227: 645651; discussion 651–653.
  • 32
    Albertini JJ,Lyman GH,Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996; 276: 18181822.
  • 33
    Morrow M,Rademaker AW,Bethke KP, et al. Learning sentinel node biopsy: results of a prospective randomized trial of 2 techniques. Surgery. 1999; 126: 714720; discussion 720–722.
  • 34
    Derossis AM,Fey J,Yeung H, et al. A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg. 2001; 193: 473478.
  • 35
    Krag D,Weaver D,Ashikaga T, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med. 1998; 339: 941946.
  • 36
    Giuliano AE,Barth AM,Spivack B,Beitsch PD,Evans SW. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg. 1996; 183: 185189.
  • 37
    Czerniecki BJ,Scheff AM,Callans LS, et al. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer. 1999; 85: 10981103.
  • 38
    Schrenk P,Shamiyeh A,Wayand W. Sentinel lymph-node biopsy compared to axillary lymph-node dissection for axillary staging in breast cancer patients. Eur J Surg Oncol. 2001; 27: 378382.
  • 39
    Dabbs DJ,Fung M,Landsittel D,McManus K,Johnson R. Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J. 2004; 10: 101105.
  • 40
    Giuliano AE,Dale PS,Turner RR,Morton DL,Evans SW,Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995; 222: 394399; discussion 399–401.
  • 41
    McGuckin MA,Cummings MC,Walsh MD,Hohn BG,Bennett IC,Wright RG. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer. 1996; 73: 8895.
  • 42
    Chadha M,Chabon AB,Friedmann P,Vikram B. Predictors of axillary lymph node metastases in patients with T1 breast cancer. A multivariate analysis. Cancer. 1994; 73: 350353.
  • 43
    Gajdos C,Tartter PI,Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg. 1999; 230: 692696.
  • 44
    Barth A,Craig PH,Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer. 1997; 79: 19181922.
  • 45
    Anan K,Mitsuyama S,Tamae K,Nishihara K,Iwashita T,Abe Y, et al. Axillary lymph node metastases in patients with small carcinomas of the breast: is accurate prediction possible? Eur J Surg. 2000; 166: 610615.
  • 46
    Bedrosian I,Mick R,Orel SG, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer. 2003; 98: 468473.
  • 47
    Lehman CD,Gatsonis C,Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007; 356: 12951303.
  • 48
    Lee SG,Orel SG,Woo IJ, et al. MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology. 2003; 226: 773778.
  • 49
    Liberman L,Morris EA,Kim CM, et al. MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. AJR Am J Roentgenol. 2003; 180: 333341.
  • 50
    Saslow D,Boetes C,Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007; 57: 7589.
  • 51
    Rosser RJ. A point of view: trauma is the cause of occult micrometastatic breast cancer in sentinel axillary lymph nodes. Breast J. 2000; 6: 209212.
  • 52
    Bleiweiss IJ,Nagi CS,Jaffer S. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol. 2006; 24: 20132018.
  • 53
    Mansel RE,Fallowfield L,Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98: 599609.